CD274 and cancer: In the 4T1-bearing immunocompetent mouse model, the combined administration of TEM and anti-PD-L1 antibodies induced anti-cancer immunity, which activated T cells by inhibiting circulating sEV PD-L1 and cellular PD-L1 levels.